What is claimed is:

1. The use of a TNFR25 agonist for the manufacture of a medicament for delaying acute rejection of a transplanted allograft, wherein the TNFR25 agonist is an agonistic anti-TNFR25 antibody that specifically binds to TNFR25.

~~2. The use of claim 1, wherein the TNFR25 agonist is an antibody that specifically binds TNFR25.~~

~~3~~2. The use of claim ~~2~~1, wherein the anti-TNFR25 antibody is a monoclonal antibody.

~~4~~3. The use of claim ~~3~~2, wherein the monoclonal antibody is of the IgG isotype.

~~5~~4. The use of any one of the preceding claim~~s 1~~, wherein the administration is by injection.

5. The use of any one of the preceding claims, wherein the TNFR25 agonist increases regulatory T cell proliferation.